Another year, another set of financing transactions that provide a lifeline to the struggling company.
News & Analysis: Amyris
The synthetic biology pioneer launched an important new product, but it faces immense competition.
Ramping up production of its zero-calorie sweetener has proved expensive. Can the company rein in costs?
The filings provide a glimpse of the company's struggles. Can cannabinoids pull the business out of the doldrums?
The company filed its annual report for 2018 and gave a brief update on first-half 2019 operations.
An overlooked announcement provides an opportunity for a management team that has lost the trust of investors.
The company hopes new products in development and a reshuffled debt portfolio can deliver long-awaited growth and profits. Investors have heard that before.
Another day, another transaction. Is the synthetic biology pioneer better positioned to execute now?
The business received a small lifeline from one of its largest shareholders.
Shares of the synthetic biology pioneer have risen and fallen by double digits many days in recent weeks.